Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Cash from Financing Activities (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Cash from Financing Activities for 5 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 7.11% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 53.91% year-over-year, with the annual reading at $6.0 million for FY2025, 53.91% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.4 million at Werewolf Therapeutics, down from $3.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $110.2 million in Q2 2021, with the low at -$9.7 million in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $10.7 million, with a median of $1.3 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities tumbled 1504.62% in 2024, then surged 54666.67% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $38000.0 in 2021, then surged by 3205.26% to $1.3 million in 2022, then surged by 622.37% to $9.1 million in 2023, then tumbled by 71.93% to $2.5 million in 2024, then fell by 7.11% to $2.4 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $2.4 million, $3.3 million, and $388000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.